Cedars-Sinai Heart Institute, Los Angeles, CA, USA.
Am J Transplant. 2012 Nov;12(11):2875-91. doi: 10.1111/j.1600-6143.2012.04223.x. Epub 2012 Aug 17.
The field of heart transplantation has seen significant progress in the past 40 years. However, the breakthroughs in long-term outcome have seen stagnation in the past decade. Through advances in genomics and transcriptomics, there is hope that an era of personalized transplant therapy lies in the future. To see where heart transplantation truly fits into the long term, searching for and understanding the alternative approaches for heart failure therapy is both important and inevitable. The application of mechanical circulatory support has contributed to the largest advancement in treatment of end stage heart failure. It has already been approved for destination therapy of heart failure, and greater portability and ease of use of the device will be the future trend. Although it is still not prime time for stem cell therapy, clinical experiences have already suggested its potential therapeutic effects. And finally, whole organ engineering is on the horizon as new techniques have opened the way for this to proceed. In the end, progress on alternative therapies largely depends on our deeper understanding of the mechanisms of heart failure and how to prevent it.
在过去的 40 年里,心脏移植领域取得了重大进展。然而,在过去的十年中,长期结果的突破已经停滞不前。通过基因组学和转录组学的进步,人们希望个性化移植治疗的时代即将到来。为了真正了解心脏移植在长期治疗中的地位,寻找和理解心力衰竭治疗的替代方法既重要又不可避免。机械循环支持的应用为终末期心力衰竭的治疗带来了最大的进展。它已经被批准用于心力衰竭的终末期治疗,设备的更大便携性和易用性将是未来的趋势。尽管干细胞疗法还不是最佳时机,但临床经验已经表明了其潜在的治疗效果。最后,随着新技术为这项工作开辟了道路,整个器官工程即将实现。最终,替代疗法的进展在很大程度上取决于我们对心力衰竭机制以及如何预防心力衰竭的更深入理解。